Home Angiogenesis HIF

HIF Modulators

Cat.No. Product Name Information Product Use Citations Product Validations
S1007 Roxadustat (FG-4592) Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. This compound also potentiates RSL3 induced ferroptosis. Phase 3.
Immunity, 2025, S1074-7613(25)00139-6
Cell Stem Cell, 2025, S1934-5909(25)00338-8
Mol Cell, 2025, 85(15):2973-2987.e6
Verified customer review of Roxadustat (FG-4592)
S2919 IOX2 IOX2 (JICL38) is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) with IC50 of 21 nM in a cell-free assay, >100-fold selectivity over JMJD2A, JMJD2C, JMJD2E, JMJD3, or the 2OG oxygenase FIH.
Cell Rep Med, 2024, 5(2):101400
Int J Mol Sci, 2024, 26(1)117
Oncogene, 2022, 41(13):1944-1958
Verified customer review of IOX2
S8138 Molidustat (BAY 85-3934) Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. This compound is in Phase 2.
Nat Cancer, 2024, 10.1038/s43018-024-00761-w
J Med Chem, 2024, 67(6):4525-4540
Sci Adv, 2024, 10(35):eadq2366
Verified customer review of Molidustat (BAY 85-3934)
S8443 MK-8617 MK-8617 is an orally active pan-inhibitor of Hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively.
FEBS J, 2024, 10.1111/febs.17379
PeerJ, 2023, 11:e15591
bioRxiv, 2021, 10.1101/2021.08.26.456853
S8171 Daprodustat (GSK1278863) Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.
Emerg Microbes Infect, 2025, 2563067
Sci Adv, 2024, 10(35):eadq2366
Cell Rep, 2021, 35(3):109020
S7979 FG-2216 FG-2216 is a potent, and orally active HIF prolyl 4-hydroxylase inhibitor with IC50 of 3.9 μM for PHD2. Phase 2.
Nat Commun, 2024, 15(1):7483
J Photochem Photobiol B, 2020, 210:111980
FASEB J, 2020, 34(2):2344-2358
S6490 Vadadustat Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.
Drug Test Anal, 2020, 10.1002/dta.2917
S7483 DMOG (Dimethyloxallyl Glycine) DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.Solutions are unstable and should be fresh-prepared.
Nucleic Acids Res, 2025, 53(14)gkaf669
Cell Commun Signal, 2025, 23(1):364
Front Pharmacol, 2025, 16:1502269
Verified customer review of DMOG (Dimethyloxallyl Glycine)
S5804 N-Acetylcysteine amide (NACA) N-acetylcysteine amide is a membrane penetrating antioxidant with anti-inflamatory activity through regulation of activation of NF-κB and HIF-1α as well as modulation of ROS.
Pharmacol Res, 2025, 219:107902
iScience, 2025, 28(3):111964
Pharmacol Res Perspect, 2025, 13(3):e70120